Filtered By:
Condition: Heart Attack
Nutrition: Omega 3
This page shows you your search results in order of date.
Order by Relevance | Date
Total 63 results found since Jan 2013.
What to Know About High Triglycerides
Discussions about heart health often center around blood pressure and cholesterol, with factors like poor sleep, smoking, family history of heart disease, and chronic stress thrown in. However, there’s one variable that doesn’t get covered as often, even though it can be an important indicator of cardiovascular risk: triglycerides.
“We don’t really talk about triglycerides very much, especially compared to cholesterol, but they’re actually an essential part of understanding heart health,” says Dr. Adriana Quinones-Camacho, a cardiologist at NYU Langone Health in New York. “For some...
Source: TIME: Health - May 23, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate heart health Source Type: news
The Potential Cardiometabolic Effects of Long-Chain Omega-3 Polyunsaturated Fatty Acids: Recent Updates and Controversies
Adv Nutr. 2023 Apr 7:S2161-8313(23)00283-1. doi: 10.1016/j.advnut.2023.03.014. Online ahead of print.ABSTRACTVarious health-related effects of long-chain (LC) omega-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been suggested. LC omega-3 PUFAs reduce triglyceride levels and have anti-inflammatory, immunomodulatory, antiplatelet, and vascular protective effects. Controversially, they might help in restoring glucose homeostasis via the gut microbiota. However, previous studies have not shown the clear benefits of LC omega-3 PUFAs for cardiovascular diseases. REDUCE-IT...
Source: Atherosclerosis - April 9, 2023 Category: Cardiology Authors: Jae Hyun Bae Hyunjung Lim Soo Lim Source Type: research
The 5 Best Ways to Control High Cholesterol, According to People With the Condition
There are a variety of factors that influence cardiovascular risk—but cholesterol is one of the first things that doctors pay attention to.
Having high levels of low-density lipoprotein (LDL) cholesterol is “definitely a variable we try to manage, because it’s been shown to be problematic for heart health,” says Dr. Adriana Quinones-Camacho, a cardiologist at NYU Langone Health.
Though it’s often called the “bad” kind of cholesterol, LDL cholesterol makes up most of your body’s cholesterol stores. That means it’s not a villain on its own, but when levels start creeping ...
Source: TIME: Health - January 18, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate heart health Source Type: news
Study Protocol and Baseline Characteristics of Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid: RESPECT-EPA, The Combination of a Randomized Control Trial and an Observational Biomarker Study
CONCLUSIONS: After this study is completed, we will have further evidence on whether a highly purified EPA is effective in reducing cardiovascular events for secondary prevention or not, as well as whether if EPA/AA ratio is a predictor for future cardiovascular events.PMID:36372250 | DOI:10.1016/j.ahj.2022.11.008
Source: Cancer Control - November 13, 2022 Category: Cancer & Oncology Authors: Yuji Nishizaki Katsumi Miyauchi Hiroshi Iwata Teruo Inoue Atsushi Hirayama Kazuo Kimura Yukio Ozaki Toyoaki Murohara Kenji Ueshima Yoshihiro Kuwabara Sachiko Tanaka-Mizuno Naotake Yanagisawa Tosiya Sato Hiroyuki Daida Source Type: research
Efficacy and Safety of Omega-3 Fatty Acids in the Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis
ConclusionModerate evidence showed that the use of omega-3 fatty acids may reduce the risk of major cardiovascular events, myocardial infarction, and cardiovascular death. Compared to other types of omega-3 fatty acids supplements, we support the use of prescription EPA ethyl ester formulations for the prevention of cardiovascular disease, but the potential risk of atrial fibrillation and bleeding cannot be ignored. It is important to note that omega-3 fatty acids should be applied with caution in patients with previous myocardial infarction, which may increase the risk of stroke. Finally, omega-3 fatty acids are relativel...
Source: Cardiovascular Drugs and Therapy - September 14, 2022 Category: Cardiology Source Type: research
Eicosapentaenoic Acid for Cardiovascular Events Reduction- Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
CONCLUSIONS: Our analyses demonstrate that although EPA supplementation lowers risk of coronary revascularization more than other oils, there may not be a benefit relative to standard of care. Further, EPA reduces the risk of cardiovascular events only in comparison to mineral oil and not when compared with other placebo oils or controls. In contrast, combined EPA+DHA was associated with reduced risk of cardiovascular death compared to controls.PMID:35914996 | DOI:10.1016/j.jjcc.2022.07.008
Source: Journal of Cardiology - August 1, 2022 Category: Cardiology Authors: Yujiro Yokoyama Toshiki Kuno Sae X Morita Leandro Slipczuk Hisato Takagi Alexandros Briasoulis Azeem Latib Sripal Bangalore Sean P Heffron Source Type: research
Effects of omega-3 fatty acid on major cardiovascular outcomes: A systematic review and meta-analysis
Conclusions:
Major cardiovascular events and cardiac death risks could be avoided with the use of omega-3 fatty acid. However, it has no significant effects on the risk of all-cause mortality, myocardial infarction, and stroke.
Source: Medicine - July 29, 2022 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
ConclusionsIcosapent ethyl is cost effective for primary and secondary cardiovascular prevention at an annual price of £2064 in the UK. For PCSK9 inhibitors, price discounts or prescription restrictions are necessary to achieve cost effectiveness.Graphical abstract
Source: Clinical Drug Investigation - July 11, 2022 Category: Drugs & Pharmacology Source Type: research
